| Literature DB >> 31689932 |
Abstract
Zinc oxide (ZnO) nanoparticles have been studied as metal-based drugs that may be used for biomedical applications due to the fact of their biocompatibility. Their physicochemical properties, which depend on synthesis techniques involving physical, chemical, biological, and microfluidic reactor methods affect biological activity in vitro and in vivo. Advanced tool-based physicochemical characterization is required to identify the biological and toxicological effects of ZnO nanoparticles. These nanoparticles have variable morphologies and can be molded into three-dimensional structures to enhance their performance. Zinc oxide nanoparticles have shown therapeutic activity against cancer, diabetes, microbial infection, and inflammation. They have also shown the potential to aid in wound healing and can be used for imaging tools and sensors. In this review, we discuss the synthesis techniques, physicochemical characteristics, evaluation tools, techniques used to generate three-dimensional structures, and the various biomedical applications of ZnO nanoparticles.Entities:
Keywords: biomedical application; physicochemical characteristics; synthesis; three-dimensional structure; zinc oxide nanoparticles
Year: 2019 PMID: 31689932 PMCID: PMC6921052 DOI: 10.3390/pharmaceutics11110575
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Current applications of ZnO NPs.
| Category | Applications | References |
|---|---|---|
| Pharmaceuticals |
Soap Ointment Dental inlays Food powders | [ |
| Cosmetics—hair and skin care products |
Powders Creams UV radiation-blocking sunscreen lotions Burn ointments | [ |
| Medical devices |
Surgical/industrial adhesives Mastics Sealants | [ |
Figure 1Schematic diagram of synthesis techniques and applications for ZnO NPs. Zinc oxide NPs are synthesized via (i) physical, (ii) chemical, (iii) biological, and (iv) microfluidic processes. They are extensively applied as (i) delivery carriers, (ii) therapeutics, (iii) sensors, and (iv) imaging agents. Abbreviations: ZnO, zinc oxide; NPs, nanoparticles.
Techniques for the synthesis of ZnO NPs.
| Synthesis Technique | Advantages | Disadvantages | References | |
|---|---|---|---|---|
| Physical methods |
Arc plasma Thermal evaporation Physical vapor deposition Ultrasonic irradiation Laser ablation |
Simple Low cost Catalyst-free Industrial-scale production |
Parameter control | [ |
| Chemical methods |
Microemulsion Sol–gel Precipitation Hydrothermal method Solvothermal method Chemical vapor deposition |
Inexpensive and easy-to-handle chemical reagents Uncomplicated equipment Low energy input Easy parameter tailoring Industrial-scale production |
Surfactant use High cost of precursors | [ |
| Biological methods (green synthesis) |
Plant extracts Microorganisms Biotechnology method Biochemistry method |
Promising alternatives to chemical methods Eco-friendly Non-toxic (safer) Inexpensive organic solvents |
Nanoparticle stability Antimicrobial activity Unclear mechanism | [ |
| Microfluidic reactor-based methods |
Continuous flow Segmented flow Co-flow |
High value-added products Reproducible Non-toxic |
Parameter control | [ |
Techniques for analyzing the physicochemical properties of ZnO NPs.
| Physicochemical Characteristics | Analysis Techniques |
|---|---|
| Agglomeration/aggregation | SEM (++), TEM (++), SPM (++), MALS (+), SAXS (+/−), SMPS (++) |
| Composition | Neutron/electron scattering (+), XRD (+), ICP-MS/OES (++), SP ICP-MS (++), EDS (+), NMR (++), XRF (++), SIMS (+), EELS (+), TOF-MS/ATOF-MS (++), FTIR/RS (++), UV–Vis (+), AES (+/−) |
| Crystalline phase | SEM (+), TEM (+), Neutron/electron scattering (++), XRD (++), FTIR/RS (+; RS), TGA/DSC (+) |
| Dustiness | SD/VS (+) |
| Solubility | DLS/PCS/QELS (++), MALS (++) |
| Dispersibility | DLS/PCS/QELS (++), MALS (++) |
| Stability | DLS/PCS/QELS (++), MALS (++), ELS (++), TGA/DSC (++) |
| Particle size/size distribution | SEM (++), TEM (++), SPM (++), DLS/PCS/QELS (++), MALS (++), SAXS (+), XRD (+; volume weighted primary crystals), SP ICP-MS (++), TOF-MS/ATOF-MS (+; coupled with FFF), FTIR/RS (+; RS), UV–Vis (+; for plasmonic materials), CHDF (++), FFF/A4F/FlFFF (++), BET (+/−), CLS (++), SMPS (++) |
| Shape | SEM (++), TEM (++), SPM (++) |
| Specific surface area | TEM (+; electron tomography), SAXS (+/−), BET (++) |
| Surface chemistry | ICP-MS/OES (+/−), EDS (+), NMR (+), XPS (++), SIMS (++), EELS (++), TOF-MS/ATOF-MS (++), FTIR/RS (+), AES (++), TGA/DSC (++) |
| Surface charge/zeta potential | SPM (+/−), DLS/PCS/QELS (+), ELS (++) |
| Porosity | BET (++), Mercury intrusion (++) |
Abbreviations: SEM: scanning electron microscopy, TEM: transmission electron microscopy, SPM: scanning probe microscopy, MALS: multiangle light scattering, SAXS: small-angle X-ray scattering, SMPS: scanning mobility particle sizer, XRD: X-ray diffraction, ICP-MS: inductively coupled plasma-mass spectroscopy, OES: optical emission spectrometer, SP ICP-MS: single particle ICP-MS, EDS: energy dispersive X-ray spectroscopy, NMR: nuclear magnetic resonance, XRF: X-ray fluorescence spectrometer, SIMS: secondary ion mass spectrometry, EELS: electron energy loss spectroscopy, TOF-MS: time-of-flight mass spectrometry, ATOF-MS: aerosol TOF-MS, FTIR: Fourier-transform infrared spectroscopy, RS: Raman spectroscopy, UV–Vis: ultraviolet–visible spectroscopy, AES: Auger electron spectroscopy, TGA: thermogravimetric analysis, DSC: differential scanning calorimetry, SD: small drum rotator, VS: vortex shaker, DLS: dynamic light scattering, PCS: photon correlation spectroscopy, QELS: quasi-elastic light scattering, ELS: electrophoretic light scattering, CHDF: capillary hydrodynamic flow fractionation, FFF: field flow fractionation, A4F: asymmetrical flow field-flow fractionation, FlFFF: flow field-flow fractionation, BET: Brunauer–Emmett-Teller analysis, CLS: centrifugal liquid sedimentation.
Figure 2Schematic diagrams of multilevel porosity in ZnO NPs and their self-assembled three-dimensional structures for enhancement of photocatalysis. Multilevel pores in (A) insect and (B) leaf branching systems, followed by Murray’s law, (C) lateral and (D) top views of hierarchically porous ZnO NP network model, (E) ZnO NP aggregates and (F) layer-by-layer structure network of ZnO NPs on a solid plate. Abbreviations: ZnO, zinc oxide; NPs, nanoparticles.
Biomedical applications of ZnO NPs.
| Biomedical Application | Morphology/Structure | Test System | References |
|---|---|---|---|
|
| [ | ||
| Paclitaxel or cisplatin-ZnO | Photo-stimulated paclitaxel or cisplatin-ZnO NPs under UV-A irradiation | HNSCC cells | [ |
| VP-16-Fe3O4@ZnO:Er3+,Yb3+@β-CD | VP-16 released from Fe3O4@ZnO:Er3+,Yb3+@β-CD NPs after microwave-triggering | MCF-7 cells | [ |
| Doxorubicin-ZnO | Starch-stabilized ZnO NPs | MCF-7 cells | [ |
| Daunorubicin-ZnO | Multilamellar liposomes with hexagonal ZnO NP cores | A549 (non-small cell lung carcinoma) cells | [ |
| Aminopolysiloxane-capped ZnO NPs | K562 (sensitive leukemia) and K562/A02 (resistant leukemia) cells | [ | |
|
| [ | ||
| Vildagliptin + ZnO | Hexagonal ZnO NPs | Rats, type 2 diabetes | [ |
| ZnO | Hexagonal ZnO NPs | Rats, type 1 and 2 diabetes | [ |
|
| [ | ||
| ZnO | Self-assembled ZnO NP network structure on Si wafer under dual UV irradiation |
| [ |
| ZnO | Hexagonal ZnO NPs with/without dual UV irradiation (~100 nm, ZnO 1.0 mg/mL, UV 30 sec, 30 min incubation) | [ | |
| Gentamicin + ZnO | Mesoporous ZnO structures on Si substrates | In vitro release for 7 days | [ |
|
| [ | ||
| ZnO (74% Lyocell fiber, 19% Smart Cell sensitive fiber, and 7% spandex) | ZnO-functionalized textile (Benevit Zink+) | [ | |
| ZnO–TiO2 | ZnO NP-embedded TiO2 nanotubes | Macrophage-like RAW 264.7 | [ |
| Magnesium/epoxy resin-ZnO/poly-capro- | Multifunctional microstructure | In vitro release | [ |
|
| [ | ||
| ZnO | ZnO NPs | Skin wound closure | [ |
| Alginate/ZnO | Alginate/nano-ZnO composite bandages | Infected wounds | [ |
| ZnO | ZnO NPs | Wound dressing | [ |
| ZnO | Topical ZnO formulations | Wound dressing | [ |
| Cod liver oil/ZnO | Zincojecol | Wound dressing | [ |
|
| [ | ||
| Folic acid-ZnO QD | Folic acid-modified | KB (oral carcinoma) cells | [ |
| ZnO QD | ZnO QDs (3–4 nm) immobilized on silica nanospheres (~150–200 nm) | Photoluminescence intensity | [ |
|
| [ | ||
| ZnO | Three-dimensional interconnected ZnO nanostructures | Acetone/methanol detection | [ |
| ZnO | ZnO nano-brush and pearl chain-like nanowire | Selective/sensitive ethanol sensing | [ |
| Mn-ZnO | Interlocking | Acetone sensing | [ |
| ZnO | Aligned ZnO nanorods | Epinephrine sensing | [ |
| ZnO | ZnO electrodes on flexible porous polyimide substrates | Cardiac troponin sensing | [ |
| ZnO | ZnO nanorod field-effect transistors (FETs) | Glucose, cholesterol, and urea sensing | [ |
| Au–ZnO | Gold (Au)–ZnO hybrid NP films | Optical and impedimetric analyses | [ |
Figure 3Antibacterial effects of dual UV-MO NPs hybrid on Escherichia coli. (A) The plot of Log(CFU/mL) versus MO NPs. Dual UV was exposed for 30 s or 10 s in three cycles, while MO NPs at 1.0 mg/mL were treated for 30 min. Representative plate images of colonies after the treatment of cyclic exposure (10 s × 3) from the uncoated area and MO NPs are shown: (B) control (untreated), (C) UV (uncoated), (D) ZnO, (E) ZnTiO3, (F) MgO, and (G) CuO, -, not detected; * p < 0.05; ** p < 0.01. Reproduced with permission from Jin et al., International Journal of Nanomedicine; published by DOVE Medical Press, 2017. from ref [116]. Abbreviations: UV, ultraviolet; MO, metal oxide; NPs, nanoparticles; ZnO, zinc oxide; ZnTiO3, zinc titanate; MgO, magnesium oxide; CuO, cupric oxide.
Figure 4ZnO nanorod enhancement of ADSC proliferation based on the activation of ERK. (A) Proliferation (%) of ADSCs using ZnO nanorods at concentrations ranging from 1.56 to 25 μg/mL and (B) ERK protein expression with and without phosphorylation determined using the western blotting method. * p < 0.05; ** p < 0.01. Reproduced with permission from Jin et al., Tissue Engineering Part C: Methods; published by Mary Ann Liebert, Inc., 2016. from ref [178]. Abbreviations: ZnO, zinc oxide; ADSC, adipose-derived stem cell; ERK, extracellular-signal-regulated kinase.
Figure 5The effect of ZnO nanorods on chondrogenic differentiation in ADSCs. (A) negative control (basal medium, expressed as “-” at (D–F)), (B) positive control (chondrogenic medium and 5% Dex, expressed as “+” at (D–F)), (C) ZnO-B treatment at 6 μg/mL, and (D) absorbance of Alcian blue extracts at 610 nm and qPCR data of (E) Col II and (F) Sox-9 mRNA expression after 21 days with or without ZnO-B. Images were taken at × 40 magnification. * p < 0.05; ** p < 0.001; *** p < 0.0001. Reproduced with permission from Jin et al., Tissue Engineering Part C: Methods; published by Mary Ann Liebert, Inc., 2016. from ref [178]. Abbreviations: ZnO, zinc oxide; ADSC, adipose-derived stem cell; Dex, dextrose.